KR102906376B1 - 항혈소판 약물 및 이의 용도 - Google Patents

항혈소판 약물 및 이의 용도

Info

Publication number
KR102906376B1
KR102906376B1 KR1020257016343A KR20257016343A KR102906376B1 KR 102906376 B1 KR102906376 B1 KR 102906376B1 KR 1020257016343 A KR1020257016343 A KR 1020257016343A KR 20257016343 A KR20257016343 A KR 20257016343A KR 102906376 B1 KR102906376 B1 KR 102906376B1
Authority
KR
South Korea
Prior art keywords
mmol
present disclosure
alkyl
saturated
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020257016343A
Other languages
English (en)
Korean (ko)
Other versions
KR20250073569A (ko
Inventor
지키앙 구
유안차오 장
공신 헤
카이 호우
하오 우
Original Assignee
상하이 큐어진 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 큐어진 파마슈티컬 컴퍼니 리미티드 filed Critical 상하이 큐어진 파마슈티컬 컴퍼니 리미티드
Publication of KR20250073569A publication Critical patent/KR20250073569A/ko
Application granted granted Critical
Publication of KR102906376B1 publication Critical patent/KR102906376B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020257016343A 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도 Active KR102906376B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29
KR1020237007048A KR20230047425A (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도
PCT/CN2021/108875 WO2022022559A1 (en) 2020-07-29 2021-07-28 Antiplatelet drugs and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007048A Division KR20230047425A (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20250073569A KR20250073569A (ko) 2025-05-27
KR102906376B1 true KR102906376B1 (ko) 2025-12-30

Family

ID=80037185

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257016343A Active KR102906376B1 (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도
KR1020237007048A Ceased KR20230047425A (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237007048A Ceased KR20230047425A (ko) 2020-07-29 2021-07-28 항혈소판 약물 및 이의 용도

Country Status (14)

Country Link
US (2) US12410132B2 (cg-RX-API-DMAC7.html)
EP (2) EP4342532B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906376B1 (cg-RX-API-DMAC7.html)
CN (4) CN119552111B (cg-RX-API-DMAC7.html)
AR (1) AR123078A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021317436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3046366T3 (cg-RX-API-DMAC7.html)
IL (1) IL299979A (cg-RX-API-DMAC7.html)
MX (1) MX2023001232A (cg-RX-API-DMAC7.html)
TW (1) TWI925859B (cg-RX-API-DMAC7.html)
WO (1) WO2022022559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532B (zh) * 2023-06-29 2026-05-15 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119019320A (zh) 2024-10-29 2024-11-26 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061A (zh) 2024-11-28 2024-12-27 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119019320A (zh) 2024-10-29 2024-11-26 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061A (zh) 2024-11-28 2024-12-27 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Also Published As

Publication number Publication date
CN116194459A (zh) 2023-05-30
KR20230047425A (ko) 2023-04-07
IL299979A (en) 2023-03-01
TW202214609A (zh) 2022-04-16
JP7899159B2 (ja) 2026-08-03
CN119033782A (zh) 2024-11-29
TWI925859B (zh) 2026-05-21
KR20250073569A (ko) 2025-05-27
MX2023001232A (es) 2023-05-15
US20250333382A1 (en) 2025-10-30
EP4342532C0 (en) 2025-09-03
US20240279178A1 (en) 2024-08-22
AU2021317436A1 (en) 2023-02-23
ES3046366T3 (en) 2025-12-01
CN119552111A (zh) 2025-03-04
CA3186645A1 (en) 2022-02-03
EP4342532B1 (en) 2025-09-03
CN119552111B (zh) 2026-01-02
EP4188935A1 (en) 2023-06-07
AR123078A1 (es) 2022-10-26
WO2022022559A1 (en) 2022-02-03
CN119033782B (zh) 2025-04-25
US12410132B2 (en) 2025-09-09
EP4342532A3 (en) 2024-07-17
EP4188935A4 (en) 2024-07-17
EP4342532A2 (en) 2024-03-27
BR112023001595A2 (pt) 2023-04-04
CN117343000A (zh) 2024-01-05
JP2023535815A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
EP4342532B1 (en) Antiplatelet drugs and uses thereof
EP4382530A1 (en) Shp2 inhibitor, pharmaceutical composition comprising same, and application thereof
RU2678990C1 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
KR20240142492A (ko) 항혈소판 약물의 약학적 조성물 및 이의 용도
JPH08507049A (ja) 低脂血症性化合物1,4−チアゼピン
CA2926830A1 (en) Thiazolopyrimidinones as modulators of nmda receptor activity
WO2021231726A1 (en) Enpp1 modulators and uses thereof
EP2616460B1 (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
EP2900664B1 (en) Crystalline forms of dihydropyrimidine derivatives
CN115677507B (zh) 氟比洛芬衍生物及其在药物中的应用
CN110278711B (zh) 作为RORγ调节剂的三环砜
RU2841656C1 (ru) Антитромбоцитарные лекарственные средства и их применение
US11834413B2 (en) Antiplatelet drugs and uses thereof
KR102865307B1 (ko) 수용체 억제제, 이를 포함하는 약학적 조성물 및 그 용도
HK40117914A (en) Antiplatelet drugs and uses thereof
HK40117914B (en) Antiplatelet drugs and uses thereof
HK40090099A (en) Antiplatelet drugs and uses thereof
CS142991A3 (en) Alpha-oxopyrrolo/2,3-b/indolacetic acids, their esters, amides and analogs, process for their preparation and their application as medicaments
EA049888B1 (ru) Трициклическое дигидроимидазопиримидоновое производное, способ его получения, его фармацевтическая композиция и применение
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
HK1207081B (en) Crystalline forms of dihydropyrimidine derivatives
HK1185878B (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine

Legal Events

Date Code Title Description
A107 Divisional application of patent
A302 Request for accelerated examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)